InvestLog
DNTH Dianthus Therapeutics, Inc. logo

DNTH Dianthus Therapeutics, Inc.

Healthcare
$86.48-3.51%ClosedMarket Cap: $3.61B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

3.46

P/S

2702.50

EV/EBITDA

-15.93

DCF Value

$-2.77

FCF Yield

-3.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

94.3%

Operating Margin

-14318.0%

Net Margin

-847.5%

ROE

-1.8%

ROA

-0.9%

ROIC

-15.8%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$463.0K$-40.8M$—
Q4 null$284.0K$97.9M$—
FY null$2.0M$-162.3M$—
Q3 null$396.0K$-36.8M$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$111.91

Target (Median)

$120.00

Target Range

$55.00 - $145.00

0 Strong Buy16 Buy0 Hold0 Sell0 Strong Sell
WedbushOutperform
2026-05-06
WedbushOutperform
2026-03-12
Raymond JamesStrong Buy
2026-03-10
BairdOutperform
2026-03-10
Clear StreetBuy
2026-03-10

Trading Activity

Insider Trades

View All
Violin Jonathandirector
SellFri May 22
Soteropoulos Pauladirector
SellFri May 22
Romano Steven J.director
SellFri May 22
Read Simondirector
SellFri May 22
McGeorge Annedirector
SellFri May 22

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

—

Beta

0.09

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.

Peers

ANAB logoANABATAI logoATAIBBOT logoBBOTELVN logoELVNIMTX logoIMTXNKTR logoNKTROCS logoOCSSANA logoSANATRML logoTRMLTSHA logoTSHA